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Abstract
Background: Hypercholesterolemia is a major risk factor for cardiovascular disorders and requires specific intervention
through an adequate lifestyle (diet and physical exercise) and, if necessary, an appropriate drug treatment. Lipid-lowering
drugs, although generally efficacious, may sometimes cause adverse events. A growing attention has been devoted to the
correction of dyslipidemias through the use of dietary supplements. The aim of this study was to assess the lipid-lowering
activity and safety of a dietary supplement containing monacolin K, L-arginine, coenzyme Q10 and ascorbic acid, named
Argicolina (A), compared to a commercially available product containing monacolin K and coenzyme Q10, Normolip 5 (N).
Methods: This was a single center, controlled, randomized, open-label, cross-over clinical study enrolling 20 Caucasian
outpatients aged 18–75 years with serum LDL-C between 130 and 180 mg/dL. Patients assumed two different dietary
supplements (A and N) both containing monacolin K 10 mg for 8 weeks each, separated by a 4-week wash-out period.
Evaluated parameters were: Total cholesterol (Tot-C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein
cholesterol (HDL-C), triglycerides (TG), fasting blood glucose, aspartate aminotransferase, alanine aminotransferase,
creatinekinase, gamma-glutamyl-transpeptidase, brachial arterial pressure and heart rate, measured at the start and at
the end of each treatment period. Safety was monitored through the study.
Results: LDL-C decreased by 23.3% during treatment with N (p < 0.0001) and by 25.6% during treatment with
A (p < 0.0001); the LDL-C mean reduction was 36.4 (95% CI: 45,6–27,1) mg/dL during N treatment and 40.1
(95% CI: 49.2–30,9) mg/dL during A treatment. Tot-C decreased significantly (p < 0.0001) within each treatment period.
HDL-C increase was negligible during A whereas it was significant during N. TG diminished markedly during A and not
significantly during N. The difference between treatments was not statistically significant for all variables. No serious or
severe adverse events occurred during the study.
Conclusions: Our results confirm the clinically meaningful LDL-C lowering properties of monacolin K. At variance with
a supplement already in the market (N), the novel association (A) of monacolin K with L-arginine, coenzime Q10 and
ascorbic acid also produces a significant reduction of triglycerides without significant effects on HDL.
Trial registration: ClinicalTrials.gov ID: NCT03425630.
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Background
Cardiovascular diseases (CVDs) rank first as the current
leading cause of death [1]. Identification, prevention and
management of the risk factors for CVDs are therefore a
priority in public healthcare programs [2]. Among CVDs
risk factors, one of the most important is dyslipidemia,
primarily hypercholesterolemia, which may be corrected
through an adequate lifestyle (diet and physical exercise)
and, if necessary, an appropriate drug treatment [3]. The
results achieved with lipid-lowering drugs, however, are not
always satisfactory, and untoward effects (mainly myalgia
and myopathies) may sometimes emerge that cause patients
to discontinue the treatment [4, 5]. Over the past few years
a growing attention has been devoted to the correction of
dyslipidemias through the use of dietary supplements, either
because some patients may have milder forms of hyperchol-
esterolemia or as an alternative to statins in patients who
may have experienced side effects, although the potential
adverse effects caused by supplements have not been fully
investigated. There is evidence of a relationship between
some food constituents and a reduction in CVD incidence
[6–8]. Monacolin K is a substance obtained during rice
fermentation by the fungus Monascus purpureus, used for
thousands of years in China to produce rice wine. Fermen-
ted rice owes its red color (hence the name “red yeast
rice”) to various pigments produced by the fungus,
including monascorubramin and rubropunctamin. In
1979 Akira Endo of the Tokyo University isolated a
metabolite produced by the fungus with a strong
inhibitory activity toward the enzyme HMG-CoA
reductase (3-hydroxy-3-methyl-glutaryl coenzyme A
reductase), which mediates the step from hydroxy-
methylglutaryl coenzyme A to mevalonic acid early in
the pathway to the endogenous synthesis of choles-
terol [9]. This metabolite was later characterised as a mem-
ber of the monacolin group and identified as monacolin K,
a structural analogue of lovastatin. Several clinical studies
have demonstrated a lipid-lowering effect of monacolin K,
alone [10, 11] or in association with other compounds [12].
Studies have shown a reduction in serum total cholesterol
(Tot-C) between 12 and 30% after the administration of
products containing from 3 to 10 mg of monacolin K, for
treatments ranging from 4 weeks up to 1 year [11, 13–15].
Some of these trials have reported a lower incidence of my-
opathies compared to statins [16]. A recent metanalysis on
products containing monacolin K have shown that the
expected mean reduction, compared to placebo, was
37.5 mg/dL (95%CI, 30.9–43.7; p < 0.00001) for Tot-C and
33.6 mg/dL (95%CI, 27.5–39.8; p < 0.00001) for
LDL-cholesterol (LDL-C) [17]. A novel dietary supplement
named Argicolina (A) containing monacolin K, L-arginine,
coenzyme Q10 and ascorbic acid has been developed by
Damor Pharmaceuticals (Naples, Italy). L-arginine is an
essential aminoacid, a substrate in the synthesis of nitric
oxide (NO) catalysed by the NO-synthetase expressed in
the vessel endothelium, therefore acting as a vasodilator and
an inhibitor of platelet aggregation [18–23]. Experimental
work showed that the association of L-arginine with a statin
increased NO production by endothelial cells compared to
statin alone [24]. Coenzyme Q has antioxidant activity and
is widely used in dietary supplements for subjects with
raised lipid levels or cardiovascular risk [25]. Ascorbic acid
has antioxidant and vasoprotective activity [26, 27]. The
diverse and complementary properties of the components
of A suggest that this product may be useful in treating
subjects with hyperlipidemia or cardiovascular risk. The
aim of this study was to assess the lipid-lowering activity
and safety of the proposed formulation in patients with
mild-moderate hypercholesterolemia, compared to a com-
mercially available dietary supplement containing monaco-
lin K and coenzyme Q10 (Normolip 5: N) (ESI - Albissola
Marina, Savona, Italy). The study was conducted according
to a randomized cross-over design.
Methods
Patients selection
Between July 2016 and April 2017 eligible patients were re-
cruited among the outpatients attending the Obesity Center
of the Endocrinology Unit 1, Cisanello Hospital, Pisa, Italy.
Patients aged 18–75 years with serum LDL-C between 130
and 180 mg/dL, not significantly modified by an appropri-
ate dietetic regimen were considered eligible for the study.
Exclusion criteria were: pregnancy or breast-feeding; known
liver, renal or muscle diseases; serum triglycerides (TG)
greater than 350 mg/dL; previous cardiovascular events;
concomitant neoplastic or immunodepressive diseases; use
of lipid-lowering drugs or dietary supplements within the
last 3 weeks; concurrent use of thiazide diuretics, oral
contraceptives containing estrogen or progestogen, systemic
corticosteroids; use of psycho-active substances, drug or
alcohol abuse; neurological or psychiatric diseases that
could affect consent validity or impair the patient’s adher-
ence to the study protocol. Thirty patients, all Caucasian,
were screened. Ten were excluded during the screening
process because they did not fulfill all the inclusion criteria
(screening failure). Twenty patients were thus randomized,
10 to the A > N sequence and 10 to the N > A sequence.
Study design
The study was conducted in a single center according to
a controlled, randomized, open-label, cross-over design.
Each patient had to assume, in a randomized sequence,
both treatments (A, 1 sachet/day; N, 1 capsule/day) for
8 weeks each separated by a 4-week wash-out period.
The study plan included the initial screening visit (V1),
an entry visit at start of the first treatment period (V2), a
visit at the end of the first treatment period (V3, 56 ± 5 days
after V2), a wash-out period of 4 weeks (±5 days), a
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Fig. 1 Study flow-chart
Table 1 Characteristics of the patients at entry
all patients (19 patients) sequence N-A (10 patients) sequence A-N (9 patients)
Gender (F/M) 13/6 7/3 6/3
Age (years) 54.7 ± 9.3 (36–70) 56.2 ± 9.6 (37–69) 53.1 ± 9.2 (36–70)
Height (cm) 168 ± 11 169 ± 9 167 ± 13
Weight (Kg) 86 ± 24 84 ± 24 87 ± 26
Body Mass Index (Kg/m2) 30.3 ± 8.2 29.4 ± 8.2 31.3 ± 8.6
Data are expressed as mean ± SD (min-max range)
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visit at start of the second (crossed over) treatment
period (V4), and a visit at the end of the second
treatment period (V5, 56 ± 5 days after V4) (Fig. 1).
Tot-C, LDL-C, HDL-cholesterol (HDL-C), TG, fasting
blood glucose, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), creatinekinase (CK),
gamma-glutamyl-transpeptidase (GGT), brachial arterial
pressure and heart rate were measured at V1, V3, V4 and
V5. Blood analyses were centrally performed in the labora-
tory of the Endocrinology Unit using standard enzymatic
techniques; LDL-C was directly measured. Clinical safety
was monitored throughout the study. If required, the
patient could be re-evaluated at any time during the study,
aside of the visits scheduled.
Statistical methods
The minimum level of statistical significance was set to
p < 0.05 two-sided, therefore 95% confidence limits
(95%CIs) were calculated. All reported p-values and CIs
are two-sided.
The primary efficacy variable was the LDL-C change
between the start and the end of each treatment period,
expressed as a percentage of the initial value. Therefore,
mean and 95%CIs of changes within treatment periods
(from V2 to V3 and from V4 to V5) for the experimental
and the control treatment, irrespective of sequence, were
calculated. The main analysis was the determination of
the two-sided 95%CI of the between-treatment mean
difference in the primary variable, computationally
analogous to a paired t test. Setting 0.10 (i.e. 10% of the
initial value) as the minimum clinically relevant differ-
ence, the two treatments were considered equivalent if
the two-sided 95%CI of the difference in their LDL-C
change from baseline was entirely between − 0.10
and + 0.10. Parallel calculations were carried out on ab-
solute, rather than relative to baseline, LDL-C changes.
Tot-C and HDL-C were analyzed as described above for
LDL-C; for TG levels (which were approximately
log-normally distributed) analogous calculations were
performed on logarithmic transformations and changes
were expressed as ratios. Between-treatment compari-
sons were expressed as A − N differences for cholesterol
values and as A/N ratios for TG values. The effects on
LDL-C were additionally tested in sensitivity multivariate
analyses: variance for cross-over studies on final-baseline
changes adjusting for period effects, and analysis of
covariance on the difference between the final values
adjusted for sequence and for the difference between the
Table 2 LDL-C (mg/dL) in the 19 patients who completed the study
Argicolina Normolip Argicolina − Normolip
At start of treatment 153.1 ± 11.6 153.1 ± 14.4 0.0 (− 7.3 +7.3)
At end of treatment 113.1 ± 12.8 * 116.7 ± 15.4 * − 3.7 (−9.5 +2.1)
Δ Final–Initial −40.1 (−49.2 −30.9) −36.4 (−45.6 −27.1) −3.7 (−13.0 +5.6)
% Δ(Final–Initial) / Initial −25.6 (−31.1 –20.1) −23.3 (−28.7 −17.9) −2.3 (−7.4 +2.8)
Data are expressed as mean ± SD, (95%CI), and analyzed by Student’s t test for paired data (end vs. start of treatment), * p < 0.0001
Fig. 2 LDL-C values (mean and SD) through the study, split by
treatment sequence
Fig. 3 Individual values of LDL cholesterol (LDL-C, mg/dL) before
and after Argicolina (A) and Normolip (N) treatment
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baseline values. Efficacy analyses had to be performed in
the intention-to-treat population, i.e. all patients with at
least one post-baseline control. A sensitivity analysis of
the primary variable was also planned in the
per-protocol population, i.e. all patients without major
protocol violations. Safety results had to be reported in
all patients who had assumed at least one dose of one
study drug. Statistical analyses were performed by the
Studio Associato Airoldi Cicogna and Ghirri, Milan,
using the SAS Software version 9.4 (SAS Inc., Cary, NC).
Sample size
The sample size was calculated for the main efficacy analysis
described above, i.e. the determination of the two-sided
95%CI of the between-treatment mean difference in the
LDL-C change from baseline. Assuming a standard
deviation (SD) of the difference no greater than 0.12, based
on a previous cross-over study for the difference between
monacolin K and placebo [11], it was estimated that 18
patients were required to prove the equivalence with a
power of 0.80. This figure was rounded to 20 enrolled
patients allowing for possible exclusions from the analysis.
Results
Patients characteristics and compliance
A patient was lost to follow-up after V2 (study entry)
and was therefore excluded for analysis. No major viola-
tions of the study protocol occurred in the other 19
patients. Therefore the intention-to-treat, per-protocol
and safety populations were constituted by the same
patients. The demographic characteristics of the 19
patients included in the analysis are shown in Table 1.
The baseline characteristics of the patients assigned to
the two different sequences of treatment (A > N or
N > A) were similar, only slight differences being observed
regarding the parameters studied. Ten patients were
affected by one or more metabolic or endocrine diseases:
obesity (n = 9), hypothyroidism treated with L-thyroxine
(n = 5), and type-2 diabetes mellitus treated with metfor-
min (n = 2). Six patients were on antihypertensive therapy.
The ratio between the number of doses presumably
assumed (products delivered minus returned) and the
treatment duration in days (equivalent to the number of
doses to be taken as per the scheduled one-daily dose regi-
men), a measure of treatment compliance, was greater
than 90% in all 19 patients who completed the study.
Efficacy
LDL-C values and their changes during the study are
reported in Table 2. LDL-C decreased by 23.3% during
treatment with N and by 25.6% during treatment with
A. The A − N difference, i.e. the mean difference
between the within-period changes observed with A and
N, was − 2.3% (the minus sign meaning a greater reduc-
tion during treatment with A compared to N). The
95%CI of this difference was between − 7.4 and + 2.8%,
entirely within the interval of − 10 to + 10% defined as
clinical equivalence and used in sample size calculation.
In parallel, the absolute (i.e., not referred to the initial
value) LDL-C mean reduction was 36.4 mg/dL during N
treatment and 40.1 mg/dL during A treatment, the mean
A − N difference being − 3.7 mg/dL (95%CI, − 13.0 to
+ 5.6). LDL-C reductions within each treatment, either as
absolute values or expressed as ratio of the initial value,
were highly significant (p < 0.0001). The results of the
analysis of variance adjusting for period effects on final
−baseline LDL-C changes were very similar to those of the
main analysis above. The mean A − N difference relative to
baseline was − 2.3% (95%CI, − 7.4 to + 2.9; p = 0.36), with
p = 0.70 for the period effect. The mean absolute A − N
difference was − 3.8 mg/dL (95%CI, − 13.4 to + 5.7;
p = 0.41), with p = 0.52 for the period effect. The analysis of
Table 3 Total-C (mg/dL) in the 19 patients who completed the study
Argicolina Normolip Argicolina−Normolip
At start of treatment 221.1 ± 16.5 221.6 ± 18.0 −0.5 (−9.8 +8.8)
At end of treatment 178.3 ± 16.3* 187.0 ± 17.1* −8.7 (− 15.3 −2.1)
Δ Final–Initial −42.7 (−53.6 −31.8) −34.6 (−46.1 −23.1) −8.2 (−19.9 +3.5)
% Δ (Final–Initial) / Initial −19.0 (−23.5 −14.4) −15.2 (−19.8 −10.5) −3.8 (−8.2 +0.6)
Data are expressed as mean ± SD, (95%CI), and analyzed by Student’s t test for paired data (end vs. start of treatment), * p < 0.0001
Table 4 HDL-C (mg/dL) in the 19 patients who completed the study
Argicolina Normolip Argicolina − Normolip
At start of treatment 56.3 ± 15.6 56.6 ± 16.0 −0.3 (−2.9 +2.3)
At end of treatment 57.7 ± 15.3 59.2 ± 17.1* −1.5 (−3.5 +0.5)
Δ Final–Initial +1.4 (−0.7 +3.5) +2.6 (+0.8 +4.3) −1.2 (−3.8 +1.4)
% Δ(Final–Initial) / Initial +3.0 (−1.3 +7.3) +4.3 (+1.5 +7.1) −1.3 (−6.0 +3.3)
Data are expressed as mean ± SD, (95%CI), and analyzed by Student’s t test for paired data (end vs. start of treatment), * p < 0.01
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covariance on the difference between the final values
adjusted for sequence and for the difference between the
baseline values yielded a mean A − N absolute difference of
− 3.6 mg/dL, very close to the other estimates reported
above, but with a narrower 95%CI (− 9.7 to + 2.5; p = 0.23),
with p = 0.49 for the sequence effect and p = 0.83 for the
difference between the baseline values. No carry-over effect
was observed, based on the fact that plasma LDL-C levels
at the end of the wash-out were similar to pre-study values
(Fig. 2). Individual values at start and end of each treatment
showed a decrease of LDL-C in all patients, except for one
who changed from 146 to 150 mg/dL during the
first-period treatment with N (Fig. 3). Irrespective of treat-
ment period, decrease from abnormal (≥ 130 mg/dL) to
normal LDL-C values was obtained in 17 of 19 patients
during A treatment (89%) and in 14 of 17 during N treat-
ment (82%; 2 patients were still in the normal range after
the wash-out and remained so at the end of treatment).
Tot-C, HDL-C and TG values measured before and after
each treatment and their differences are reported in
Tables 3, 4 and 5.
Like LDL-C, Tot-C decrease within each treatment
period was always highly significant (p < 0.0001), while
the between-treatment comparison showed a slightly,
non-significantly greater reduction with A, both as
absolute value (− 8.2 mg/dL; p = 0.16) and as ratio of
baseline (− 3.8%; p = 0.086).
HDL-C increase was negligible during A and signifi-
cant during N (Table 4), whereas TG diminished mark-
edly during A and not significantly during N (Table 5);
the difference between treatments, however, was not sta-
tistically significant for both variables (p > 0.30 and
p = 0.12, respectively). The percent changes of the effi-
cacy variables from start to end of each treatment are
summarized in Fig. 4.
Safety
No serious or severe adverse events occurred during the
study; no event required treatment interruption or
remedial therapy. Moderate and transient gastrointes-
tinal disturbances occurred in three patients, two receiv-
ing N (constipation and flatulence) and one receiving A
(diarrhea). Other moderate and transient adverse events
referred by one patient each were eczema and headache
during treatment with N and myalgia during treatment
with A. Serum CK levels above the upper limit of
normal (190 U/L) were observed in three patients: one
after treatment with A (268 U/L) –previously not treated
with N, one after both A and N (276 and 246 U/L,
respectively), and one after the wash-out period between
A and N (320 U/L). No clinically significant change was
observed in the serum levels of fasting blood glucose,
AST, ALT and GGT, as well as in blood pressure and
heart rate measures.
Discussion
High cholesterol levels are a major risk factor for cardio-
vascular disorders and may require specific intervention
with the prescription of an appropriate drug treatment
[3] which has been shown to be able to reduce morbility
and mortality in large cohorts of patients [28] and prin-
cipally based on statins. Red yeast rice, obtained through
rice fermentation by the fungus Monascuspurpureus,
contains monacolin K a natural product chemically
similar to lovastatin [29]. Monacolin K, similarly to
synthetic statins, inhibits the activity of HMG-CoA
Table 5 Triglycerides (mg/dL) in the 19 patients who completed the study
Argicolina Normolip Argicolina/Normolip rate
At start of treatment 104.2 97.6 106.8 (96.3118.4)
At end of treatment 86.9* 93.1 93.3 (81.0107.4)
Final / Initial % 83.4 (72.0 96.5) 95.4 (85.9106.0) 87.4 (73.3104.1)
Data are expressed as geometric mean (95% CI) and analyzed by Student’s t test for paired data (end vs. start of treatment) after logarithmic transformation,
* p < 0.05
Fig. 4 Percent changes during A and N treatments of total
cholesterol, HDL-cholesterol LDL-cholesterol and triglycerides (TG).
Data are expressed as (final-initial) / initial values
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(3-hydroxy-3-methyl-glutaryl coenzyme A) reductase
that mediates the production of cholesterol synthesis.
In this work we have investigated the lipid lowering
capacities of a novel association containing monacolin
K, L-arginine, coenzyme Q10 and ascorbic acid.
L-arginine is an essential aminoacid with NO-mediated
vasodilating properties [18–21], coenzyme Q has antioxi-
dant activity [25] while ascorbic acid has antioxidant and
vasoprotective activity [26, 27]. The effects of this associ-
ation were compared with those of a commercially avail-
able dietary supplement containing monacolin K and
coenzyme Q10. The study was conducted according to a
rigorous randomized cross-over design. Our results were
in agreement with previous research on monacolin K
based dietary supplements and showed a statistically sig-
nificant reduction of LDL-C levels. We were able to docu-
ment a marked lowering effect of LDL-C (A: -40.1 mg/dL,
− 25,6%; N: -36,4 mg/dL, − 23,3%), in line with previous
reports [11, 13, 15, 30–32], with no difference in efficacy
between the two formulations studied. In parallel with the
reduction of LDL-C a decrease in Tot-C was documented
for both formulations, and HDL-C was increased although
reaching significant levels only with N. A significant
reduction of triglycerides levels was found exclusively for
the novel formulation tested (A). A clinically relevant
effect of monacolin K-based supplements on triglycerides
has been previously but not consistently reported [10],
since this reduction was not documented for N we specu-
late that other compounds present in A, probably
L-arginine, may have contributed to this effect [33].
Regarding side effects (adverse events) in our study 3/19
patients reported mild and transient gastrointestinal
discomfort, and in 3/19 subjects elevation of CK occurred,
with no associated myalgia. These figures are similar to
what expected and already reported in the literature [34].
Among the limitations of this study we have to men-
tion the open (not blinded) design of the study which
was chosen because of the different nature of the
pharmaceutical preparations of the compounds tested.
The relatively low number of patients enrolled is an
additional limitation, the impact of which was attenu-
ated by the crossover design.
Conclusions
Our results confirm the clinically meaningful lipid low-
ering properties of monacolin K and specifically the
efficacy of a novel association of it with L-arginine,
coenzyme Q10 and ascorbic acid. Furthermore, our
results show a good safety profile of this association.
In addition to the very effective LDL-C lowering
capacity it is worth noticing the significant reduction of
triglycerides level achieved by A, which might be due to
the presence of L-arginine in the formulation.
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